…improving nature’s own defense mechanisms
Latest releases
Apr 21, 2017:
Lytix Biopharma completes 1st combination cohort of LTX-315 and pembrolizumab in TNBC
Apr 20, 2017:
Lytix Biopharma raises in total 80 million NOK
Apr 6, 2017:
Lytix Biopharma presented 4 posters at AACR in Washington April 2017
Apr 3, 2017:
LTX-315 was presented at ICI Boston (a dedicated Cancer Immunotherapy meeting) in March 2017